The trading price of BioNTech SE (NASDAQ:BNTX) closed higher on Friday, November 19, closing at $289.75, 5.73% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $275.181 and $290.01. The company’s P/E ratio in the trailing 12-month period was 8.62. In examining the 52-week price action we see that the stock hit a 52-week high of $464.00 and a 52-week low of $80.55. Over the past month, the stock has gained 1.18% in value.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
BioNTech SE, whose market valuation is $66.46 billion at the time of this writing, is expected to release its quarterly earnings report Nov 09, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $11.65 per share this quarter, however they have predicted annual earnings per share of $41.1 for 2021 and $44.29 for 2022. It means analysts are expecting annual earnings per share growth of 58,614.30% this year and 7.80% next year.
Analysts have forecast the company to bring in revenue of $5.68 billion for the current quarter, with the likely lows of $5.08 billion and highs of $6.52 billion. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $19.63 billion. The company’s revenue is forecast to grow by 3,227.00% over what it did in 2021.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of BioNTech SE No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest BNTX has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned BNTX a recommendation rating is 16. Out of them, 9 rate it a Hold, while 5 recommend Buy, whereas 0 assign an Overweight rating. 1 analyst(s) have tagged BioNTech SE (BNTX) as Underweight, while 1 advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that BNTX’s price is currently 9.55% off the SMA20 and 3.30% off the SMA50. The RSI metric on the 14-day chart is currently showing 57.85, and weekly volatility stands at 5.67%. When measured over the past 30 days, the indicator reaches 6.73%. BioNTech SE (NASDAQ:BNTX)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 17.80. With analysts defining $155.38-$381.21 as the low and high price targets, we arrive at a consensus price target of $274.73 for the trailing 12-month period. The current price is about 46.37% off the estimated low and -31.57% off the forecast high, based on this estimate. Investors will be thrilled if BNTX’s share price rises to $276.66, which is the median consensus price. At that level, BNTX’s share price would be 4.52% above current price.
To see how BioNTech SE stock has been performing in comparison to its peers in the industry, here are the numbers: BNTX stock’s performance was 5.73% in the latest trading, and 205.22% in the past year. BioNTech SE has a P/E ratio of 8.62. Also in last trading session, the S&P 500 Index has plunged -0.14%, while the Dow Jones Industrial also saw a negative session, down -0.75% on the day.
An evaluation of the daily trading volume of BioNTech SE (NASDAQ:BNTX) indicates that the 3-month average is 3.17 million.
Currently, records show that 244.37 million of the company’s shares remain outstanding. The insiders hold 1.18% of outstanding shares, whereas institutions hold 17.20%. However, since the stock’s price has seen 255.43% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.